Walter, B. and Rogenhofer, S. and Vogelhuber, M. and Berand, A. and Wieland, W. F. and Andreesen, R. and Reichle, A. (2010) Modular therapy approach in metastatic castration-refractory prostate cancer. WORLD JOURNAL OF UROLOGY, 28 (6). pp. 745-750. ISSN 0724-4983,
Full text not available from this repository. (Request a copy)Abstract
The present multi-center phase II study was designed to support the hypothesis that networking agents, which bind to ubiquitous accessible targets in metastatic castration-refractory prostate cancer (CRPC) may counteract neoplasia-specific aberrant cellular functions, thereby mediating PSA response (primary endpoint). Patients with metastatic CRPC received low-dose chemotherapy with capecitabine 1 g twice daily plus dexamethasone 1 mg daily for 14 days every 3 weeks, COX-2 blockade with rofecoxib 25 mg (or etoricoxib 60 mg) daily combined with pioglitazone 60 mg daily until disease progression. Thirty-six consecutive patients with metastatic CRPC were enrolled, of whom n = 18 (50%) had been extensively pretreated with radio- or radionuclid therapy and n = 16 (44%) with chemotherapies; n = 8 patients (22%) were medically none-fit, having an ECOG-score of 0-2. Nine of 15 patients with PSA response > 50% showed objective response. Median time to PSA response was 2.4 months (range 1.0-7.3 months). Two of 9 patients responding with PSA < 4 ng/ml showed complete resolution of skeletal lesions after 9 and 16 months; 13 patients had a stable course of disease, and 5 patients experienced progressive disease. Median progression-free survival (PFS) was 4.0 months (2.8-5.1 months) and median overall survival (OS) 14.4 months (10.7-17.2 months). Toxicities according to WHO grade II were noticed in 9 patients. This new combined modular therapy approach is able to induce major responses including resolution of skeletal lesions in patients with CRPC. Furthermore, the study may clinically support the above-mentioned hypothesis.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LOW-DOSE DEXAMETHASONE; CLINICAL-TRIALS; PHASE-II; DOCETAXEL; CARCINOMA; MITOXANTRONE; PREDNISONE; CAPECITABINE; EXPRESSION; PATHWAYS; Castrate-resistant prostate cancer; Modular therapy; Anti-inflammatoric agents |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 07 Jul 2020 05:06 |
| Last Modified: | 07 Jul 2020 05:06 |
| URI: | https://pred.uni-regensburg.de/id/eprint/23844 |
Actions (login required)
 |
View Item |
